Skip to main content

Table 2 Adverse events

From: Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

Adverse events

Any grade, number (%)

Grade 3, number (%)

Hypertension

7 (38.9)

1 (5.6)

Proteinuria

5 (27.8)

2 (11.1)

Hypothyroidism

3 (16.7)

0

General malaise

3 (16.7)

0

Hand-foot syndrome

2 (11.1)

0

Anemia

1 (5.6)

0

Stomatitis

1 (5.6)

0

Renal impairment

1 (5.6)

0